Latest Breaking News On - Analyst recommendations for tarsus pharmaceuticals - Page 1 : comparemela.com

Tarsus Pharmaceuticals, Inc (NASDAQ:TARS) Receives $49 88 Consensus Price Target from Brokerages

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) has been given a consensus rating of “Moderate Buy” by the eight brokerages that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12-month target price […]

United statesBryan wahlBobakr azamianArtisan partners limited partnershipHedge funds weigh in on tarsus pharmaceuticalsSecurities exchange commissionTarsus pharmaceuticals stock downJennison associatesNews ratings for tarsus pharmaceuticals dailyJefferies financial groupPricet rowe associates incGoldman sachs groupHealthcare of ontario pension plan trust fundDeerfield management companylp seriesTarsus pharmaceuticalsAnalyst recommendations for tarsus pharmaceuticals

Tarsus Pharmaceuticals, Inc (NASDAQ:TARS) Given Consensus Recommendation of Moderate Buy by Analysts

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) has received an average recommendation of “Moderate Buy” from the eight analysts that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average twelve-month price objective among brokerages […]

United statesBobakr azamianBryan wahlVanguard group incGoldman sachs groupTarsus pharmaceuticals trading downNews ratings for tarsus pharmaceuticals dailyHealthcare of ontario pension plan trust fundInstitutional trading of tarsus pharmaceuticalsTarsus pharmaceuticals incTarsus pharmaceuticalsAnalyst recommendations for tarsus pharmaceuticalsAsset management gp ltdJefferies financial groupJennison associatesSecurities exchange commission

Oppenheimer Raises Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target to $61 00

Oppenheimer Raises Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target to $61 00
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United statesAziz mottiwalaSeshadri neervannanFinancial servicesProshare advisorsNews ratings for tarsus pharmaceuticals dailyTarsus pharmaceuticals incTarsus pharmaceuticals company profileAnalyst recommendations for tarsus pharmaceuticalsGoldman sachs groupBleakley financial groupSecurities exchange commissionLord abbettTarsus pharmaceuticals stock performanceTarsus pharmaceuticalsInstitutional trading of tarsus pharmaceuticals

Tarsus Pharmaceuticals (NASDAQ:TARS) PT Raised to $61 00

Tarsus Pharmaceuticals (NASDAQ:TARS) PT Raised to $61 00
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United statesZurcher kantonalbank zurich cantonalbankSeshadri neervannanBryan wahlHedge funds weigh in on tarsus pharmaceuticalsAnalyst recommendations for tarsus pharmaceuticalsTarsus pharmaceuticals incTarsus pharmaceuticals stock downNews ratings for tarsus pharmaceuticals dailyRaymond james associatesIeq capitalChina universal asset management coGoldman sachs groupTower research capitalJefferies financial groupTarsus pharmaceuticals

Tarsus Pharmaceuticals, Inc (NASDAQ:TARS) Receives Average Rating of Moderate Buy from Brokerages

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) have received a consensus rating of “Moderate Buy” from the eight research firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month […]

United statesBobakr azamianBryan wahlZurcher kantonalbank zurich cantonalbankGoldman sachs groupNews ratings for tarsus pharmaceuticals dailyTower research capitalTarsus pharmaceuticalsTarsus pharmaceuticals price performanceAnalyst recommendations for tarsus pharmaceuticalsTarsus pharmaceuticals company profileChina universal asset management coTarsus pharmaceuticals incIeq capitalRaymond james associatesSecurities exchange commission